🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Denmark / NCT02434900
Active, not recruiting Observational

Vitamin D and Angiogenic Markers in Odense Child Cohort 1

NCT02434900 · tracked via the Priya Life Science Denmark tracker
Sponsor
Odense University Hospital
Phase
Observational
Started
2010-01
Last updated
2015-05-06

Condition(s) studied

Abortion, Spontaneous

Study summary

The Vitamin D and Angiogenic Marker Study 1:

Vitamin D and angiogenic markers in early pregnancy. Epidemiology and associations to early-pregnancy miscarriage

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Pregnant and residing in the municipality of Odense during 2010-2012 Exclusion Criteria: * Not residing in Odense, leaving the municipality

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
HCA Research, Odense University Hospital Odense Denmark

More Odense University Hospital trials in Denmark

Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue Recruiting
The Safe Fast Track Study Recruiting
Severe Lung Disease in Childhood Recruiting
Continuous Bloodsugar Monitoring System With a Sensor Compared to Fingerstick Bloodsugar Monitoring Recruiting
Optimised Cardiovascular and Renal Protection in Patients With Chronic Kidney Disease and Cardiovascular Disease Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02434900 on ClinicalTrials.gov ↗ ← All trials in Denmark